公开(公告)号：KR1020090058403A

公开(公告)日：2009-06-09

申请号：KR1020070125161

申请日：2007-12-04

Applicant: 한국생명공학연구원

Inventor： 류성언 ,  정대균 ,  윤태성 ,  문정희 ,  홍석일 ,  홍영준

IPC: G01N33/573 ,  G01N33/53

CPC classification number: G01N33/573 ,  C07K16/18 ,  C07K16/40 ,  C12N9/16 ,  G01N33/57484 ,  G01N2333/916

Abstract: A method for diagnosing disease by quantitative monitor of protein tyrosinase phosphatase (PTP) is provided to verify the state of disease and health through measuring the PTP amount and profiling in a bio sample. A method for diagnosing disease, such as cancer, by the quantitative monitor of protein tyrosinase phosphatase (PTP) comprise: a step of hydrolyzing a sample from a individual suffering from cancer; a step of adding syhthesis standard peptide which is substituted with one or more isotope of biomarker in the sample; a step of isolating the synthesis standard peptide and wild-type from samples and performing quantitative analysis; a step of comparing the amount of synthesis standard peptide with the amount of peptide expression of wild-type and calculating the absolute value of the expression amount of wild-type; and a step of confirming the difference with normal individual.

Abstract translation: 通过定量监测蛋白质酪氨酸磷酸酶（PTP）来诊断疾病的方法，通过测量生物样品中的PTP量和分析来提供疾病状况和健康状态。 通过蛋白质酪氨酸磷酸酶（PTP）的定量监测来诊断疾病如癌症的方法包括：从患有癌症的个体中水解样品的步骤; 在样品中加入由一种或多种生物标记同位素取代的拟合标准肽的步骤; 从样品中分离合成标准肽和野生型并进行定量分析的步骤; 将合成标准肽的量与野生型肽的表达量进行比较并计算野生型的表达量的绝对值的步骤; 并确认与正常个体差异的步骤。

公开(公告)号：KR102172810B1

公开(公告)日：2020-11-02

申请号：KR1020190104626

申请日：2019-08-26

Applicant: 한국생명공학연구원

Inventor： 윤선우 ,  정대균

IPC: C12Q1/70 ,  C12Q1/6818

公开(公告)号：KR101768600B1

公开(公告)日：2017-08-17

申请号：KR1020150069077

申请日：2015-05-18

Applicant: 한국생명공학연구원

Inventor： 정대균 ,  송대섭 ,  김정기

IPC: A61K39/12 ,  A61K48/00 ,  A61K39/39

CPC classification number: A61K38/16 ,  A61K39/12 ,  A61K39/39 ,  A61K48/00

Abstract: 본발명은인플루엔자표면단백질인헤마글루티닌단백질의 HA2 헬리컬도메인을이용한범용성개 인플루엔자바이러스백신조성물및 개인플루엔자감염질환의예방또는치료용약학적조성물에관한것이다. 본발명의서열번호 3으로표시되는폴리펩티드및 서열번호 1의 379 내지 474 잔기로표시되는폴리펩티드는대장균에서대량생산이가능하고다양한개 인플루엔자아형에대하여중화항체를효과적으로생산할수 있을뿐만아니라복합투여를통해기존개 인플루엔자백신의면역유도효과를증강시킬수 있으므로인플루엔자아형및 신종변이인플루엔자에대한범용성백신으로널리활용될수 있다.

公开(公告)号：KR101637955B1

公开(公告)日：2016-07-08

申请号：KR1020150069106

申请日：2015-05-18

Applicant: 한국생명공학연구원

Inventor： 정대균 ,  송대섭 ,  김정기

IPC: C07K14/11 ,  C07K16/10 ,  A61K39/145 ,  A61K39/395

CPC classification number: A61K39/145 ,  A61K39/395 ,  A61P31/16 ,  C07K14/11 ,  C07K16/10 ,  C07K16/1018

Abstract: 본발명은인플루엔자표면단백질인헤마글루티닌단백질의 HA2 헬리컬도메인을이용한범용성인플루엔자바이러스백신조성물및 인플루엔자감염질환의예방또는치료용약학적조성물에관한것이다. 본발명의서열번호 3으로표시되는폴리펩티드및 서열번호 1의 379 내지 474 잔기로표시되는폴리펩티드는대장균에서대량생산이가능하고다양한인플루엔자아형에대하여중화항체를효과적으로생산할수 있으므로, 인플루엔자아형및 신종변이인플루엔자에대한범용성백신으로널리활용될수 있다.

Abstract translation: 本发明涉及一种使用流感病毒表面蛋白的血凝素蛋白HA2螺旋结构域的多功能流感病毒疫苗组合物。 本发明还涉及用于预防或治疗流感感染的药物组合物。 由序列号3表示的多肽和由序列号1的379-474个残基表示的多肽可以在大肠杆菌中大量生产，并且能够有效地产生针对各种流感亚型的中和抗体。 因此，该肽可广泛用作流感亚型和新型流感突变体的多功能疫苗。

公开(公告)号：KR1020130128640A

公开(公告)日：2013-11-27

申请号：KR1020120052506

申请日：2012-05-17

Applicant: 한국생명공학연구원

Inventor： 정대균 ,  윤태성 ,  강성현 ,  경아영 ,  김송이 ,  류성언 ,  박황서 ,  이승구

IPC: A61K31/4025 ,  A61K31/40 ,  A61K31/34 ,  A61P3/10

CPC classification number: A61K31/4025 ,  A61K31/341 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/429 ,  Y10S514/866

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes containing a compound which is denoted by chemical formula 1 or chemical formula 2. The compound which is denoted by the chemical formula 1 or chemical formula has excellent activity for controlling PTPMT1, and is capable of being used as the composition for the prevention and treatment of diabetes.

Abstract translation: 本发明涉及用于预防和治疗含有化学式1或化学式2的化合物的糖尿病药物组合物。由化学式1或化学式表示的化合物具有优异的控制PTPMT1的活性， 并且能够用作预防和治疗糖尿病的组合物。

公开(公告)号：KR1020090063866A

公开(公告)日：2009-06-18

申请号：KR1020070131385

申请日：2007-12-14

Applicant: 한국생명공학연구원

Inventor： 류성언 ,  박황서 ,  정숙경 ,  정대균 ,  이상협 ,  김승준 ,  반영재

IPC: A61K31/506 ,  A61P35/00

CPC classification number: C07D405/06 ,  C07D239/62 ,  C07D405/04

Abstract: A composition for preventing and treating cancer, which contains a pyrimidine derivative is provided to suppress the protein phosphatase activation related to dephosphorylation, prevent and treat cancer. A composition for preventing and treating cancer, which suppresses protein phosphatase comprises a pyrimidine derivative of the chemical formula 1 or its pharmaceutically allowable salt. The pharmaceutically allowable salt is an acid addition salt which is formed by pharmaceutically allowable free acid. The protein phosphatase is Cdc25A[cell division cycle 25A], Cdc25B, Cdc25C, PTP1B[protein tyrosine phosphatase 1B], Prl-3[phosphatase of regenerating liver], LAR[leukocyte antigen-related], CD45[cluster of differentiation 45], Yop[Yersinia enterocolytica tyrosine phosphatase], PP1[protein phosphatases 1], or VHR[vaccinia human-related]. The cancer caused by protein phosphatase is breast cancer, rectal cancer, non-Hodgkin's lymphoma, prostate cancer, pancreatic ductal adenocarcinoma, lung cancer, and bone marrow cancer.

Abstract translation: 提供含有嘧啶衍生物的用于预防和治疗癌症的组合物以抑制与去磷酸化相关的蛋白磷酸酶活化，预防和治疗癌症。 用于预防和治疗癌症的组合物，其抑制蛋白质磷酸酶包括化学式1的嘧啶衍生物或其药学上可允许的盐。 药学上允许的盐是由药学上允许的游离酸形成的酸加成盐。 蛋白磷酸酶是Cdc25A [细胞分裂周期25A]，Cdc25B，Cdc25C，PTP1B [蛋白酪氨酸磷酸酶1B]，Prl-3 [再生肝磷脂酶]，LAR [白细胞抗原相关]，CD45 [分化簇45] Yop [肠耶路撒毒素酪氨酸磷酸酶），PP1 [蛋白磷酸酶1]或VHR [痘苗人相关]。 由蛋白磷酸酶引起的癌症是乳腺癌，直肠癌，非霍奇金淋巴瘤，前列腺癌，胰腺导管腺癌，肺癌和骨髓癌。

公开(公告)号：KR1020060060376A

公开(公告)日：2006-06-05

申请号：KR1020040099431

申请日：2004-11-30

Applicant: 한국생명공학연구원

Inventor： 안종석 ,  오현철 ,  배은영 ,  김보연 ,  김범석 ,  오원근 ,  김민수 ,  류성언 ,  정대균

IPC: C12N1/14

Abstract: 본 발명은 신규한 곰팡이 균주 마이크로뮤코 라만니아너스 바르 앙굴리스포러스 (
Micromucor ramannianus var.
angulisporus ) CRM000232 (KCTC 10696BP), 및 이로부터 분리·정제한 뎁시드계 화합물을 유효성분으로 하는 단백질 티로신 탈인산화 효소 1Ｂ 저해제에 관한 것이다.
본 발명에 따른 곰팡이 균주 CRM000232(KCTC 10696BP)로부터 분리·정제한 뎁시드계 화합물은 단백질 티로신 탈인산화 효소 1B 저해 활성이 우수하고, 혈당강하효과가 우수함으로 당뇨병 예방 및 치료에 유용하게 사용할 수 있으며, 특히 제 2형 당뇨병인 인슐린 비의존형 당뇨병에 대하여 치료효과가 뛰어나다.